Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells $27,151.99 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,459 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total value of $27,151.99. Following the completion of the sale, the chief financial officer directly owned 158,285 shares in the company, valued at $2,945,683.85. This trade represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Thomas Catinazzo also recently made the following trade(s):

• On Monday, July 6th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.69, for a total value of $331,130.73.
• On Monday, June 22nd, Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $3,176,156.11.
• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $12.86, for a total transaction of $227,840.62.

Relay Therapeutics Stock Down 3.2%

NASDAQ:RLAY opened at $18.83 on Friday. The stock has a market cap of $3.61 billion, a price-to-earnings ratio of -11.99 and a beta of 1.67. Relay Therapeutics, Inc. has a 52 week low of $3.03 and a 52 week high of $20.79. The company’s 50 day moving average price is $17.16 and its 200-day moving average price is $13.07.

Relay Therapeutics (NASDAQ:RLAY) last issued its earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.58 million. As a group, sell-side analysts anticipate that Relay Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on RLAY shares. UBS Group set a $26.00 target price on shares of Relay Therapeutics in a research note on Tuesday, May 19th. Zacks Research downgraded shares of Relay Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Canaccord Genuity Group initiated coverage on shares of Relay Therapeutics in a research report on Thursday, July 16th. They issued a “buy” rating and a $29.00 target price for the company. The Goldman Sachs Group lifted their price objective on Relay Therapeutics from $22.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Citigroup reissued an “outperform” rating on shares of Relay Therapeutics in a report on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $24.92.

Institutional Investors Weigh In On Relay Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of RLAY. SG Americas Securities LLC boosted its stake in Relay Therapeutics by 591.7% during the fourth quarter. SG Americas Securities LLC now owns 220,949 shares of the company’s stock worth $1,869,000 after buying an additional 189,004 shares during the period. Tudor Investment Corp ET AL purchased a new stake in Relay Therapeutics in the third quarter worth $399,000. Sanctuary Advisors LLC bought a new stake in shares of Relay Therapeutics during the fourth quarter worth $1,203,000. Affinity Asset Advisors LLC purchased a new stake in shares of Relay Therapeutics during the first quarter valued at $3,980,000. Finally, Elmind Capital LP purchased a new stake in shares of Relay Therapeutics during the fourth quarter valued at $4,543,000. 96.98% of the stock is owned by institutional investors.

More Relay Therapeutics News

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Potential earnings catalyst: Zacks expects Relay Therapeutics could exceed consensus expectations in its upcoming quarterly report, which may support near-term investor sentiment. This is only an earnings preview, not a reported result. Relay Therapeutics Expected to Beat Earnings Estimates
• Positive Sentiment: Breast cancer program draws renewed interest: Coverage says Relay’s breast cancer program has revitalized the investment story, potentially expanding the company’s opportunity in oncology. Relay Therapeutics Revitalized by Breast Cancer Program
• Positive Sentiment: Institutional ownership and analyst support remain strong: Several funds increased their positions during the first quarter, and recent analyst targets generally imply additional upside. MarketBeat reports a “Moderate Buy” consensus rating with an average target of $24.92.
• Neutral Sentiment: Second-quarter results are scheduled for August 6: Relay will report financial results and corporate updates after the market close. Investors will likely focus on pipeline progress, cash resources and development plans. Relay Therapeutics Second-Quarter Results Announcement
• Neutral Sentiment: Insider selling was administrative: CFO Thomas Catinazzo and insiders Donald Bergstrom and Peter Rahmer sold a combined 4,444 shares at $18.61 to cover tax withholding on vested equity awards. Each retained substantial holdings, limiting the bearish significance of the transactions. Relay Therapeutics Insider Transactions
• Negative Sentiment: Competition and clinical risk remain material: Relay is still a clinical-stage biotechnology company, and its valuation depends heavily on successful trials and eventual commercialization. Intense competition in breast cancer could limit the program’s upside.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.